A Phase 2 interventional study of Niraparib in Prostatic Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 110 sites in 15 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing niraparib in Prostatic Neoplasms — 3 open to participants now, 7 under way, 2 of them phase 3. niraparib · Prostatic Neoplasms.
Among the 19 studies testing niraparib in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2016, is one of 8 in phase 2, and was the 3rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 19 studies testing niraparib in Prostatic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
University of British Columbia · Sites in United States, Canada
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Karolinska Institutet · Sites in Belgium, Norway, Sweden and 1 more country
Ages 18+ · Men only
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 2
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 289 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 34 across the 19 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 16th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2016, is one of 20 in phase 2, and was the 54th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
3 of the studies testing niraparib in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
| NCT04812366University of British ColumbiaGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing niraparib in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.
This is a multicenter and open-label (participants and researchers are aware of the treatment that participants are receiving) study that consists of 4 phases: a Prescreening Phase for biomarker evaluation only, a Screening Phase, a Treatment Phase (Cycle 1 Day 1 and will continue until the study drug is discontinued), a Follow-up Phase (every 3 months after end of treatment visit), and a Long-term Extension Phase (until participants no longer derive benefit from treatment or until further notification on different means of study treatment). Participants will be monitored for safety during the study period, and up to 30 days after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 300 milligram (mg) niraparib (3 capsules\*100 mg) orally once daily.
Drug: Niraparib
Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
Also known as: JNJ-64091742
Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation
ORR defined as percentage of participants with BRCA DNA-repair anomalies and measurable disease whose best response is either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and with no evidence of bone progression per Prostate Cancer Working Group 3 (PCWG3) criteria.
Time frame: Up to 52 months
Objective Response Rate for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Non-Breast Cancer Gene (BRCA) Mutation
ORR defined as percentage of participants with BRCA deoxyribonucleic acid (DNA)-repair anomalies and measurable disease whose best response is either CR or PR per RECIST 1.1 and with no evidence of bone progression per PCWG3 criteria.
Time frame: Up to 52 months
Circulating Tumor Cells (CTC) Response Rate
CTC response rate was defined as the percentage of participants with CTC equals to (=) 0 per 7.5 milliliter (mL) blood at 8 weeks post-baseline in participants with baseline CTC greater than (\>) 0.
Time frame: At 8 weeks post-baseline
Overall Survival (OS)
OS is defined as time from enrollment to death from any cause.
Time frame: Up to 52 months
Radiographic Progression-Free Survival (rPFS)
rPFS was defined as time from enrollment to radiographic progression or death from any cause, whichever occurred first. Radiographic progression was evaluated per RECIST 1.1 criteria for soft tissue disease and per PCWG3 criteria for bone disease.
Time frame: Up to 52 months
Time to Radiographic Progression
Time to radiographic progression is defined as time from enrollment to radiographic progression or death due to disease progression, whichever occurs first. Disease progression is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
Time frame: Up to 52 months
Time to Prostate-Specific Antigen (PSA) Progression
Time to PSA progression was defined as time from enrollment to the first date of documented PSA progression based on PCWG3 criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanograms per milliliter (ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks.
Time frame: Up to 52 months
Time to Symptomatic Skeletal Event (SSE)
Time to SSE was defined as the time from enrollment to first occurrence of one of the following symptomatic skeletal events: tumor-related spinal cord compression, radiation to bone to relieve skeletal symptoms, surgery to bone or need for tumor-related orthopedic surgical intervention, symptomatic or pathologic fracture.
Time frame: Up to 52 months
Duration of Objective Response
Duration of objective response is defined as time from CR or PR to radiographic progression of disease, unequivocal clinical progression or death, whichever occurs first. Unequivocal clinical progression defined as one or more of following: 1) deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS) to Grade 3 or higher; 2) need to initiate any of following because of tumor progression (even in absence of radiographic evidence of disease): alternative anticancer therapy for prostate cancer, radiation therapy, surgical interventions for complications due to tumor progression.
Time frame: Up to 52 months
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
Time frame: Up to 52 months
Number of Participants With Worst Toxicity Grades for Clinical Laboratory Tests Based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Number of participants with worst toxicity grades for clinical laboratory tests (chemistry and hematology) based on NCI-CTCAE were reported. The chemistry laboratory parameters were: alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased and the hematology parameters were: hemoglobin increased, lymphocyte count increased. Grading was done as: Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening).
Time frame: Up to 52 months
| Milestone | Niraparib |
|---|---|
| Started | 289 |
| Intent to treat participants (breast cancer gene [brca] and non-brca participants) | 223 |
| Completed | 0 |
| Not completed | 289 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 208 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by subject | 24 |
| Withdrew: Other | 45 |
| Withdrew: Physician decision | 6 |
ORR defined as percentage of participants with BRCA DNA-repair anomalies and measurable disease whose best response is either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and with no evidence of bone progression per Prostate Cancer Working Group 3 (PCWG3) criteria.
| percentage of participants | Niraparib |
|---|---|
| Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation | 34.2 (23.7 to 46.0) |
ORR defined as percentage of participants with BRCA deoxyribonucleic acid (DNA)-repair anomalies and measurable disease whose best response is either CR or PR per RECIST 1.1 and with no evidence of bone progression per PCWG3 criteria.
| percentage of participants | Niraparib |
|---|---|
| Objective Response Rate for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Non-Breast Cancer Gene (BRCA) Mutation | 10.6 (3.5 to 23.1) |
CTC response rate was defined as the percentage of participants with CTC equals to (=) 0 per 7.5 milliliter (mL) blood at 8 weeks post-baseline in participants with baseline CTC greater than (\>) 0.
| percentage of participants | Niraparib |
|---|---|
| BRCA | 23.7 |
| Non-BRCA | 8.5 |
OS is defined as time from enrollment to death from any cause.
| months | Niraparib |
|---|---|
| BRCA | 13.01 (11.04 to 14.29) |
| Non-BRCA | 9.63 (8.05 to 13.44) |
rPFS was defined as time from enrollment to radiographic progression or death from any cause, whichever occurred first. Radiographic progression was evaluated per RECIST 1.1 criteria for soft tissue disease and per PCWG3 criteria for bone disease.
| months | Niraparib |
|---|---|
| BRCA | 8.08 (5.55 to 8.38) |
| Non-BRCA | 3.71 (1.97 to 5.49) |
Time to radiographic progression is defined as time from enrollment to radiographic progression or death due to disease progression, whichever occurs first. Disease progression is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
| months | Niraparib |
|---|---|
| BRCA | 8.08 (5.75 to 8.97) |
| Non-BRCA | 3.78 (2.00 to 5.55) |
Time to PSA progression was defined as time from enrollment to the first date of documented PSA progression based on PCWG3 criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanograms per milliliter (ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks.
| months | Niraparib |
|---|---|
| BRCA | 5.13 (4.60 to 5.59) |
| Non-BRCA | 3.65 (2.83 to 3.71) |
Time to SSE was defined as the time from enrollment to first occurrence of one of the following symptomatic skeletal events: tumor-related spinal cord compression, radiation to bone to relieve skeletal symptoms, surgery to bone or need for tumor-related orthopedic surgical intervention, symptomatic or pathologic fracture.
| months | Niraparib |
|---|---|
| BRCA | 13.80 (10.41 to NA) |
| Non-BRCA | 10.35 (8.18 to NA) |
Duration of objective response is defined as time from CR or PR to radiographic progression of disease, unequivocal clinical progression or death, whichever occurs first. Unequivocal clinical progression defined as one or more of following: 1) deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS) to Grade 3 or higher; 2) need to initiate any of following because of tumor progression (even in absence of radiographic evidence of disease): alternative anticancer therapy for prostate cancer, radiation therapy, surgical interventions for complications due to tumor progression.
| months | Niraparib |
|---|---|
| BRCA | 5.55 (3.91 to 7.20) |
| non-BRCA | 5.16 (2.14 to NA) |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
| Participants | Niraparib |
|---|---|
| Number of Participants With Adverse Events (AEs) | 288 |
Number of participants with worst toxicity grades for clinical laboratory tests (chemistry and hematology) based on NCI-CTCAE were reported. The chemistry laboratory parameters were: alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased and the hematology parameters were: hemoglobin increased, lymphocyte count increased. Grading was done as: Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening).
| Participants | Niraparib |
|---|---|
| ALT increased (Grade 1 or 2) | 67 |
| ALT increased (Grade 3 or 4) | 4 |
| Alkaline phosphatase increased (Grade 1 or 2) | 102 |
| Alkaline phosphatase increased (Grade 3 or 4) | 7 |
| AST increased (Grade 1 or 2) | 70 |
| AST increased (Grade 3 or 4) | 4 |
| Blood bilirubin increased (Grade 1 or 2) | 9 |
| Blood bilirubin increased (Grade 3 or 4) | 2 |
| Creatinine increased (Grade 1 or 2) | 45 |
| Creatinine increased (Grade 3 or 4) | 2 |
| GGT increased (Grade 1 or 2) | 105 |
| GGT increased (Grade 3 or 4) | 14 |
| Hemoglobin increased (Grade 1 or 2) | 0 |
| Hemoglobin increased (Grade 3 or 4) | 0 |
| Lymphocyte count increased (Grade 1 or 2) | 6 |
| Lymphocyte count increased (Grade 3 or 4) | 0 |
Collected over Up to 52 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niraparib | 208/289 (72%) | 134/289 (46.4%) | 280/289 (96.9%) |
| Event | Niraparib |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 17/289 |
| AnaemiaBlood and lymphatic system disorders | 13/289 |
| General Physical Health DeteriorationGeneral disorders | 8/289 |
| VomitingGastrointestinal disorders | 7/289 |
| Back PainMusculoskeletal and connective tissue disorders | 7/289 |
| HeadacheNervous system disorders | 6/289 |
| Spinal Cord CompressionNervous system disorders | 6/289 |
| HaematuriaRenal and urinary disorders | 6/289 |
| ConstipationGastrointestinal disorders | 5/289 |
| NauseaGastrointestinal disorders | 5/289 |
| Event | Niraparib |
|---|---|
| NauseaGastrointestinal disorders | 167/289 |
| AnaemiaBlood and lymphatic system disorders | 154/289 |
| VomitingGastrointestinal disorders | 109/289 |
| FatigueGeneral disorders | 105/289 |
| ConstipationGastrointestinal disorders | 98/289 |
| ThrombocytopeniaBlood and lymphatic system disorders | 94/289 |
| Decreased AppetiteMetabolism and nutrition disorders | 93/289 |
| Back PainMusculoskeletal and connective tissue disorders | 59/289 |
| NeutropeniaBlood and lymphatic system disorders | 54/289 |
| Weight DecreasedInvestigations | 50/289 |
| Age, Continuous(years) | Niraparib |
|---|---|
| Mean | 68.8 ± 7.8 |
| Sex: Female, Male(Participants) | Niraparib |
|---|---|
| Female | 0 |
| Male | 289 |
| Race/Ethnicity, Customized(Participants) | Niraparib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 16 |
| Black or African American | 9 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 205 |
| More than one race | 3 |
| Unknown or Not Reported | 51 |
| Other | 5 |
| Region of Enrollment(Participants) | Niraparib |
|---|---|
| AUSTRALIA | 31 |
| BELGIUM | 18 |
| BRAZIL | 12 |
| CANADA | 21 |
| DENMARK | 1 |
| FRANCE | 48 |
| ISRAEL | 6 |
| NETHERLANDS | 6 |
| RUSSIAN FEDERATION | 7 |
| SOUTH KOREA | 5 |
| SPAIN | 39 |
| SWEDEN | 24 |
| TAIWAN | 9 |
| UNITED KINGDOM | 17 |
| UNITED STATES | 45 |
Showing the first 100 of 110 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Jan 2021, 52 months.
Results were first posted in Mar 2022, 1 year 1 month after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 52 months is above that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niraparib
Janssen Research & Development, LLC →